Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
Open Access
- 10 August 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 103 (6), 759-764
- https://doi.org/10.1038/sj.bjc.6605845
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Improved Surgical Outcomes for Breast Cancer Patients Receiving Neoadjuvant Aromatase Inhibitor Therapy: Results from a Multicenter Phase II TrialJournal of the American College of Surgeons, 2009
- PIK3CAandPIK3CBInhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor–Positive Breast CancerCancer Research, 2009
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsJNCI Journal of the National Cancer Institute, 2008
- Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancerBritish Journal of Cancer, 2007
- Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast CancerJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002